7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines - Patent # RE40183

Resources

Home

Browse by:

7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines

RE40183	7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines

Patent Drawings:
Inventor:	Hlavka, et al.
Date Issued:	March 25, 2008
Application:	11/145,508
Filed:	June 3, 2005
Inventors:	Hlavka; Joseph J. (Tuxedo Park, NY) Sum; Phaik-Eng (Pomona, NY) Gluzman; Yakov (Upper Saddle River, NJ) Lee; Ving J. (Los Altos, CA) Ross; Adma A. (Airmont, NY)
Assignee:	Wyeth Holdings Corporation (Madison, NJ)
Primary Examiner:	Badio; Barbara P.
Assistant Examiner:
Attorney Or Agent:
U.S. Class:	514/152; 540/200; 544/154; 546/195; 548/263.2; 548/267.6; 548/300.4; 548/316.4; 548/356.5; 548/538; 549/487; 552/203; 552/205
Field Of Search:	514/152; 552/203; 552/205; 540/200; 544/154; 546/195; 549/487; 548/263.2; 548/267.6; 548/538; 548/316.4; 548/300.4; 548/356.5
International Class:	A61K 31/65; C07C 233/64
U.S Patent Documents:
Foreign Patent Documents:	109 850; 901107; WO 84/01895; WO 89/02270
Other References:	Chopra, Handbook of Experimental Pharmacology, vol. 78, 317-392, Springer-Verlag (1985). cited by examiner. Levy, Antimicrobial Agents and Chemotheraphy, vol. 33 No. 8, 1373-1374 (Aug. 1989). cited by examiner. Salyers, Molecular Microbiology 4(1), 151-156 (1990). cited by examiner. Adamson et al., "Aplastic Anemia," Hematology 4.sup.th ed., Williams WJ et al, eds.; McGraw Hill, New York (1990) pp. 158-174. cited by other. Allen, "Minocycline," Ann. Intern. Med. 85:482-487 (1976). cited by other. Altemeier et al., "Intra-abdominal Abscesses, " American Journal of Surgery 125:70-79 (1973). cited by other. Bell, "Oral Penicillins in the Treatment of Chronic Staphylococcal Osteomyelitis," Lancet 10:295-297 (1968). cited by other. Benitz et al., "Morphologic Effects of Minocycline in Laboratory Animals, " Toxicol. Appl. Pharmacol. 11:150-170 (1967). cited by other. Bennion et al., "Gangrenous and Perforated Appendicitis with Peritonitis: Treatment and Bacteriology," Clinical Therapeutics 12(Suppl C):31-44 (1990). cited by other. Bocker et al., "Identification and Determination of the Principal Metabolites of Minocycline in Humans," J. Chromatogr. 568:363-374 (1991). cited by other. Bohnen et al., "Prognosis in Generalized Peritonitis. Relation to Cause and Risk Factors," Archives of Surgery 118:285-290 (1983). cited by other. Boothe et al., "6-Deoxytetracyclines, I. Chemical Modification by Electrophilic Substitution" J. Am. Chem. Soc., 82:1253-1254 (1960). cited by other. Bryant et al., "Increased Frequency of Doxycycline Side Effects," Pharmacotherapy 7:125-129 (1987). cited by other. Buyske et al., "Concentration and Persistence of Tetracycline and Chlortetractycline in Bone," J. Pharmacol. Exper. Ther. 130:150-156 (1960). cited by other. Ciancio et al., "An Evaluation of Minocycline in patients with Periodontal Disease", Journal of Periodontology 51:530-534 (1980). cited by other. Collins, "Cell-Free Synthesis of Proteins Coding for Mobilisation functions of colE1 and Transportation" Gene 6:28-42 (1979). cited by other. Conte et al., "Steady-State Serum and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Tigecycline," Int. J. Antimicrob. Agents 25(6):523-529 (2005). cited by other. Degenkolb et al., "Structural Requirements of Tetracycline-tet Repressor Interaction: Dermination of Equilibrium Binding Constants for Tetracycline Analogs with the Tet Repressor", Antimicrob. Agents Chemother. 35:1591-1595 (1991). cited by other. DeJonge et al., "Inhibition of Mitochondrial-Protein Synthesis in Rat Small-Intestinal Epithelium," Eur. J. Biochem. 32:356-364 (1973). cited by other. Dietz et al., "Comparative Toxicity and Carcinogenicity Studies of Tetracycline and Oxytetracycline in Rats and Mice," Fund. Appl. Toxicol. 17:335-346 (1991). cited by other. Entwistle et al., "Reduction of Nitro-compounds", J. Chem. Soc. 1:443 (1977). cited by other. Fanning et al., "Distressing Side-effects of Minocycline Hydrochloride," Arc Intern Med. 136:761-762 (1976). cited by other. Feigin, "Clindamycin Treatment of Osteomyelitis and Septic Arthritis in Children," Pediatr. 55:213-223 (1975). cited by other. Fry et al., "Determinants of Death in Patients with Intraabdominal Abscess, " Surgery 88:517-523 (1980). cited by other. Garrison, "Histamine, Bradykinin, 5-Hydroxytryptamine, and Their Antagonists," In: Gilman AG, Rall TW et al., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics 8.sup.th ed. Elmsford, NY: Pergamon Press pp. 575-582 (1990). cited byother. Gilbaldi et al., Pharmacokinetics, 2.sup.nd ed., "One-Compartment", Marcel Dekker, Inc., NY, 1982, pp. 1-43. cited by other. Gorbach, "Antimicrobial Prophylaxis for Appendectomy and Colorectal Surgery," Reviews of Infectious Diseases 13(Suppl 10):S815-S820 (1991). cited by other. Gugler et al., "Effects of Antacids on the Clinical Pharmacokinetics of Drugs. An Update," Clin. Pharmacokinet. 18:210-219 (1990). cited by other. Gump et al., "Side Effects of Minocycline: Different Dosage Regimen," Antimicrob Agents Chemother. 12:642-646 (1977). cited by other. Hlavka et al., "The 6-Deoxytetracyclines. III Electrophilipic and Nucleophilic Substitution", J. Am. Chem. Soc., 84:1426-1430 (1962). cited by other. Jonas et al., "Minocycline," Ther. Drug Monit. 4:137-145 (1982). cited by other. Kantrowitz et al., "Histamine-Mediated Myocardial Damage in Rabbits," J. Mol. Cell. Cardiol. 14:551-555 (1982). cited by other. King, "Animal Models in the Study of Vomiting, " Can. J. Physiol. Pharmacol. 68:260-268 (1990). cited by other. Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, (1989). cited by other. Loeliger et al., "Reliability and Clinical Impact of the Normalization of the Prothrombin Times in Oral Anticoagulant Control", Thrombosis & Haemostasis 53:148-154 (1985). cited by other. MacDonald et al., "Pharmacokinetic Studies on Minocycline in Man," Clinical Pharmacology and Therapeutics 14:852-861 (1973). cited by other. Misgen, "Compatibilities and Incompatibilities of Some Intravenous Solution Admixtures", Am. J. Hosp. Pharm. 22:92-94 (1965). cited by other. Mitscher; "The Chemistry of the Tetracyline Antibiotic", Marcel Dekker, Inc. Chapter 6.3, p. 172-173 and Chapter 2, p. 53-54, (1978). cited by other. Monnier et al., "Visual Compatability of Heparin with Selected Intravenous Admixtures", ASHP Midyear Clinical Meeting, vol. 25, p. P-186E (Dec. 1990). cited by other. Mosdell et al., "Antibiotic Treatment for Surgical Peritonitis," Annals of Surgery 214:543-549 (1991). cited by other. Morrison et al., "Amines I. Preparation and Physical Properties", Organic Chemistry, 4.sup.th ed., pp. 894, 898-900, 902 (1983). cited by other. Nelis et al., "Metabolism of Minocyclinein Humans, " Drug Metab Dispos. 10:142-146 (1982). cited by other. Noble et al., "Short-term Toxicity and Observation on Certain Aspects of the Pharmacology of a Unique Tetracycline--Minocycline," Toxicol Appl. Pharmacol. 11:128-149 (1967). cited by other. Norden, "Lessons Learned from Animal Models of Osteomyelitis," Rev. Infect. Dis. 10:103-110 (1988). cited by other. Norden, "Experimental Chronic Staphylococcal Osteomyelitis in Rabbits: Treatment with Rifampin Alone and in Combination with Other Antimicrobial Agents," Rev. Infect. Dis. 5(Suppl 3):S491-S494 (1983). cited by other. Norden et al., "Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus with Vancomycin and Rifampin," J. Infect. Dis. 147:352-357 (1983). cited by other. Norden et al., "Clindamycin Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus," J. Infect. Dis. 153:956-959 (1986). cited by other. Norden et al., "Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus with Ampicillin/Sulbactam," J. Infect. Dis. 161:52-53 (1990). cited by other. Pawelczyk et al., "Kinetics of Drug Decomposition Part 74.Kinetics of Degradation of Minocycline in Aqueous Solution", Pharmacol. Pharm. 34:409-421 (1982). cited by other. Pratt, Coupled TranScription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B.D. Hames and S.J. Higgins, eds.) p. 179-209, IRL Press, Oxford-Washington, (1984). cited by other. Raasch, "Interaction of Oral Antibiotics and Common Chronic Medications" Geriatrics 42:69-74 (1987). cited by other. Remmers et al., "Some Observations on the Kinetics of the C.4 Epimerization of Tetracycline," J. Pharm. Sci., 52:752-756 (1963). cited by other. Robertson, "p-Aminophenyllacetic Acid", Org. Syn. Coll. 1:52 (1941). cited by other. Rissing, "Animal Models of Osteomyelitis: Knowledge, Hypothesis and Speculation," Infect. Dis. Clin. North Am. 4:377-390 (1990). cited by other. Skillman et al., "Respiratory Failure, Hypotension, Sepsis, and Jaundice. A Clinical Syndrome Associated with Lethal Hemorrhage from Acute Stress Ulceration of the Stomach," American Journal of Surgery 117:523-530 (1969). cited by other. Slama et al., "Oral Ciprofloxacin Therapy for Osteomyelitis Caused by Aerobic Gram Negative Bacilli," Am. J. Med. 82(Suppl 4A):259-261 (1987). cited by other. Solomkin et al., "Results of a Multicenter Trial Comparing Imipenem/Cilastatin to Tobramycin/Clindamycin for Intra-abdominal Infections," Annals of Surgery 212:581-591 (1990). cited by other. Spencer et al., "6-Deocytetracyclines,. V. 7,9-Disubstituted Products", J. Med. Chem. 6:405-407 (1963). cited by other. Sum et al., "Synthesis of Novel Tetracycline Derivatives with Substitution at the C-8 Position," Tetrahedron Letters vol. 35, No. 12, pp. 1835-1836 (1994). cited by other. Swenson et al. "The Bacteriology of Intra-abdominal Infections," Archives of Surgery 109:398-399 (1974). cited by other. Tapp et al., "Tetracycline Toxicity," Experientia 22:530-531 (1966). cited by other. Tice, "Outpatient Parenteral Antimicrobial Therapy for Osteomyelitis," Infect. Dis. Clin. North Am. 12:903-919 (1998). cited by other. Van Den Bogert et al., "Tissue distribution and Effects on Mitochondrial Protein Synthesis of Tetracyclines After Prolonged Continuous Intravenous Administration to Rats," Biochem. Pharmacol. 30:1706-1709 (1981). cited by other. Waldvogel, "Osteomyelitis," In Gorbach SL et al., eds. Infectious Diseases, Saunders, Philadelphia 1339-1344 (1988). cited by other. Westfall et al., "Formulation of a Stable Trace Element Solution for TPN" Am. J. Hosp. Pharm. 37:1620 (1980). cited by other. Watson, "Chloramphenicol Toxicity in Dogs," Research in Veterinary Science 23:66-69 (1977). cited by other. Williams et al., "Minocycline: Possible Vestibular Side-Effects," Lancet. 2:744-746 (1974). cited by other. Woodward, "m-Hydroxybenzaldehyde", Org. Syn. Coll. 3:453 (1955. cited by other. Yuen, et al., "Kinetics of Concomitatnt Degradation of Tetracycline to Epitetracycline to Epitetracycline, Anhydrotetracycline, and Epianhydrotetracycline in Acid Phospate Solution", J. Pharm, Sci. 66:1648-1650 (1977). cited by other. Zubay, "In-vitro Synthesis of Protein in Microbial Systems", Ann. Rev. Genet. 7:267-287 (1973). cited by other. The Merck Index, Entries #2111 and 5936 10.sup.th Ed. (1983) pp. 300,301, & 869. cited by other. World Health Organization Technical Report Series 687-1-184 (1983). cited by other.

Abstract:	The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula ##STR00001## wherein R, X, R.sup.5 and R.sup.6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.
Claim:	We claim: 1. A compound of the formula ##STR00223## wherein: X is selected from amino, NR.sup.1 R.sup.2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R.sup.1is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R.sup.2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR.sup.1R.sup.2 and R.sup.1=hydrogen, R.sup.2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R.sup.1=methyl or ethyl; R.sup.2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or2-methylpropyl; and when R.sup.1=n-propyl, R.sup.2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R.sup.1=1-methylethyl, R.sup.2=n-butyl, 1-methylpropyl or 2-methylpropyl; and when R.sup.1=n-butyl, R.sup.2=n-butyl,1-methylpropyl or 2-methylpropyl; and when R.sup.1=1-methylpropyl, R.sup.2=2-methylpropyl; R is selected from R.sup.4 (CH.sub.2).sub.n CO-- or R.sup.4' (CH.sub.2).sub.n SO.sub.2--; and n=0-4; and when R=R.sup.4(CH.sub.2).sub.n CO-- and .[.n-0.]. .Iadd.n=0.Iaddend., R.sup.4 is selected from amino; monosubstituted amino selected from straight or branched (C.sub.1-C.sub.6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino,diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); a substituted (C.sub.3-C.sub.6)cycloalkyl group with substitution selected from cyano, aminoor (C.sub.1-C.sub.3)acyl; a substituted (C.sub.6-C.sub.10)aryl group with substitution selected from halo, (C.sub.1-C.sub.4)alkoxy, trihalo (C.sub.1-C.sub.3)-alkyl, nitro, amino, cyano, (C.sub.1-C.sub.4)alkoxycarbonyl (C.sub.1-C.sub.3)alkylamino orcarboxy; .alpha.-amino-(C.sub.1-C.sub.4)alkyl selected from aminomethyl, .alpha.-aminoethyl, .alpha.-aminopropyl or .alpha.-amino-butyl; carboxy (C.sub.2-C.sub.4)-alkylamino selected from aminoacetic acid, .alpha.-aminobutyric acid or.alpha.-aminopropionic acid and the optical isomers thereof; (C.sub.7-C.sub.9)aralkylamino; (C.sub.1-C.sub.4)alkoxycarbonylamino substituted (C.sub.1-C.sub.4) alkyl group; .alpha.-hydroxy(C.sub.1-C.sub.3)alkyl selected from hydroxymethyl,.alpha.-hydroxyethyl or .alpha.-hydroxy-1-methylethyl or .alpha.-hydroxypropyl; .alpha.-mercapto (C.sub.1-C.sub.3)alkyl selected from mercaptomethyl, .alpha.-mercaptoethyl, .alpha.-mercapto-1-methylethyl or .alpha.-mercaptopropyl; halo-(C.sub.1-C.sub.3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ringwith two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and anadjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C.sub.3-C.sub.6)cycloalcylcarbonyl, (C.sub.6-C.sub.10)aroyl selected from benzoyl or naphthoyl; halo substituted(C.sub.6-C.sub.10)aroyl; (C.sub.1-C.sub.4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C.sub.1-C.sub.4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straightor branched butoxycarbonyl or allyloxycarbonyl; a substituted vinyl group with substitution selected from halogen, halo(C.sub.1-C.sub.3)alkyl, or a substituted (C.sub.6-C.sub.10)aryl group with substitution selected from halo, (C.sub.1-C.sub.4)-alkoxy,trihalo(C.sub.1-C.sub.3)alkyl, nitro, amino, cyano, (C.sub.1-C.sub.4)alkoxycarbonyl, (C.sub.1-C.sub.3)alkylamino or carboxy; (C.sub.1-C.sub.4)alkoxy group; C.sub.6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected fromhalo, (C.sub.1-C.sub.4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C.sub.1-C.sub.3)alkylamino; (C.sub.7-C.sub.10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C.sub.1-C.sub.4)alkyl, cyano, carboxy, or(C.sub.6-C.sub.10)aryl selected from phenyl, .alpha.-naphthyl, or .beta.-naphthyl; R.sup.aR.sup.b amino(C.sub.1-C.sub.4)alkoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl,1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or .[.(CH.sub.2).sub.2W(CH.sub.2)2--.]. (.Iadd.CH.sub.2).sub.2W(CH.sub.2).sub.2--.Iaddend. wherein W is selected from --N(C.sub.1-C.sub.3)alkyl, O,S, --NH, --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl; or R.sup.aR.sup.b aminoxy group, wherein R.sup.aR.sup.b is straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl,1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)alkyl, O, S, --NH, --NOB and B is selected from hydrogen or(C.sub.1-C.sub.3)alkyl; and when R=R.sup.4 (CH.sub.2).sub.nCO-- and n=1-4, R.sup.4 is selected from amino; a substituted (C.sub.3-C.sub.6)cycloalkyl group with substitution selected from cyano, amino or (C.sub.1-C.sub.3)acyl; asubstituted(C.sub.6-C.sub.10)-aryl group with substitution selected from halo, (C.sub.1-C.sub.4)-alkoxy, trihalo(C.sub.1-C.sub.3)alkyl, nitro, amino, cyano, (C.sub.1-C.sub.4)alkoxycarbonyl, (C.sub.1-C.sub.3)alkylamino or carboxy; acyloxy or haloacyloxygroup selected from acetyl, propionyl, chloroacetyl, trichlorocetyl, (C.sub.3-C.sub.6)cycloalkylcarbonyl, (C.sub.6-C.sub.10)aroyl selected from benzoyl or naphthoyl, halo substituted (C.sub.6-C.sub.10)aroyl, (C.sub.1-C.sub.4)alkylbenzoyl, or(heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C.sub.1-C.sub.4)alkoxy; C.sub.6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C.sub.1-C.sub.4)-alkyl, nitro, cyano, thiol, amino, carboxy,di(C.sub.1-C.sub.3)-alkylamino; (C.sub.7-C.sub.10)aralkyloxy; (C.sub.1-C.sub.3)alkylthio group selected from methylthio, ethylthio, propylthio or allythio; C.sub.6-arylthio group selected from phenylthio or substituted phenylthio with substitutionselected from halo, (C.sub.1-C.sub.4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C.sub.1-C.sub.3)alkylamino; C.sub.6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo,(C.sub.1-C.sub.4)alkoxy, trihalo(C.sub.1-C.sub.3)alkyl, nitro, amino, cyano, (C.sub.1-C.sub.4)alkoxycarbonyl, (C.sub.1-C.sub.3)alkylamino or carboxy; (C.sub.7-C.sub.8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono-or di-straight or branched chain (C.sub.1-C.sub.6)-alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl,3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C.sub.2-C.sub.5)azacycloalkyl group; a carboxy(C.sub.2-C.sub.4) alkylamino group with thecarboxy alkyl selected from aminoacetic acid, .alpha.-aminopropionic acid, .alpha.-aminobutyric acid and the optical isomers thereof; .alpha.-hydroxy(C.sub.1-C.sub.3)alkyl selected from hydroxymethyl, .alpha.-hydroethyl or .alpha.-hydroxy-1-methylethylor .alpha.-hydropropyl; halo(C.sub.1-C.sub.3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C.sub.3-C.sub.6)cycloalkylcarbonyl; (C.sub.6-C.sub.10)aroyl selected from benzoyl or naphthoyl; halosubstituted (C.sub.6-C.sub.10)aroyl; (C.sub.1-C.sub.4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove; (C.sub.1-C.sub.4)alkoxycarbonylamino.[.,.]. group selected from tert-butoxycarbonylamino, allyloxycarbonylamino,methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C.sub.1-C.sub.4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R.sub.aR.sup.b-amino(C.sub.1-C.sub.4)alkoxy group wherein R.sup.aR.sup.b is straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is .[.(CH).sub.m.]. (.Iadd.CH.sub.2).sub.m .Iaddend.m=2-6 or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)-alkyl, O, S, --NH, --NOB, and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl; or R.sup.aR.sup.b aminoxy group, whereinR.sup.aR.sup.b is straight or branched (C.sub.1-C.sub.4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein Wis selected from --N(C.sub.1-C.sub.3)-alkyl, O, S, --NH, --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl, and when .[.R.dbd.R.sup.4' (CH.sub.2)SO.sub.2--.]. .Iadd.R.dbd.R.sup.4' (CH.sub.2).sub.nSO.sub.2--.Iaddend. and n=0 R.sup.4' isselected from amino; monosubstituted amino selected from straight or branched (C.sub.1-C.sub.6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino,ethyl(1-methylethyl)amino, monomethylbenzlamino, piperidinyl, morpholinyl, 1-imidazoyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); a substituted (C.sub.3-C.sub.6)cycloalkyl group with substitution selected from cyano, amino or(C.sub.1-C.sub.3)acyl; halo(C.sub.1-C.sub.3)alkyl group; a heterocycle as defined hereinabove; R.sup.aR.sup.b amino (C.sub.1-C.sub.4)alkoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)-alkyl selected from methyl, ethyl,n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W--(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3) alkyl, O, S, --NH, --NOB and B is selected fromhydrogen or (C.sub.1-C.sub.3)-alkyl; or R.sup.aR.sup.b aminoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sup.4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, or 2-methyl-propyl orR.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)alkyl, O, S, .[.--NY.]. .Iadd.--NH.Iaddend., --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3) alkyl; and whenR.dbd.R.sup.4' (CH.sub.2).sub.nSO.sub.2-- and n=1-4, R.sup.4' is selected from (C.sub.1-C.sub.4)carboxyalkyl; a substituted (C.sub.3-C.sub.6)cyclalkyl group with substitution selected from cyano, amino or (C.sub.1-C.sub.3)-acyl; (C.sub.1-C.sub.4)alkoxy; C.sub.6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C.sub.1-C.sub.3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C.sub.1-C.sub.3) alkylamino; (C.sub.7-C.sub.10)aralkyoxy; R.sup.aR.sup.b amino (C.sub.1-C.sub.4) alkoxy, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is(CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)alkyl, O, S, .[.--NY.]. .Iadd.--NH .Iaddend.or --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl; or R.sup.aR.sup.b aminoxygroup, wherein R.sup.aR.sup.b is straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or--(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)alkyl, O, S, --NH, --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl; (C.sub.1-C.sub.3) alkylthio selected from methylthio, ethylthio or n-propylthio; C.sub.6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C.sub.1-C.sub.3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C.sub.1-C.sub.3)alkylamino; (C.sub.7-C.sub.8) aralkylthio; a heterocycle asdefined hereinabove; hydroxy; mercapto; mono- or di-straight or branched (C.sub.1-C.sub.6)alkyl- amino group the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl,1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C.sub.1-C.sub.3) alkyl; acyl or haloacylselected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C.sub.3-C.sub.6) cycloalkylcarbonyl; (C.sub.6-C.sub.10) aroyl selected from benzoyl or naphthoyl; halo substituted (C.sub.6-C.sub.10)aroyl, (C.sub.1-C.sub.4) alkylbenzoyl, or(heterocycle) carbonyl, the heterocycle as defined hereinabove; (C.sub.1-C.sub.4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R.sup.5 isselected from hydrogen; straight or branched (C.sub.1-C.sub.3) alkyl selected from methyl, ethyl n-propyl or 1-methylethyl; (C.sub.6-C.sub.10)aryl selected from phenyl, .alpha.-naphthyl or .beta.-naphthyl; (C.sub.7-C.sub.9) aralkyl group; aheterocycle as defined hereinabove; or --(CH.sub.2).sub.nCOOR.sup.7 where n=0-4 and R.sup.7 is selected from hydrogen; straight or branched (C.sub.1-C.sub.3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C.sub.6-C.sub.10)arylgroup selected from phenyl, .alpha.-naphthyl or .beta.-naphthyl; R.sup.6 is selected from hydrogen, straight or branched (C.sub.1-C.sub.3)alkyl group selected form methyl, ethyl, n-propyl or 1-methylethyl; (C.sub.6-C.sub.10)aryl group selected fromphenyl, .alpha.-naphthyl or .beta.-naphthyl; (C.sub.7-C.sub.9)-aralkyl group; a heterocycle as defined hereinabove; or .[.--CH.sub.2).sub.n(COOR.sup.7'.]. .Iadd.--(CH.sub.2).sub.nCOOR.sup.7'.Iaddend. where n=0-4 and R.sup.7' is selected fromhydrogen; straight or branched (C.sub.1-C.sub.3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C.sub.6-C.sub.10)aryl selected from phenyl, .alpha.-naphthyl or .beta.-naphthyl; with the proviso that R.sup.5 and R.sup.6 cannot both behydrogen ; or R.sup.5 and R.sup.6 taken together are --(CH.sub.2).sub.2W(CH.sub.2).sub.2--, wherein W is selected from (CH.sub.2).sub.q and q=0-1, --NH, --N(C.sub.1-C.sub.3)-alkyl, --N(C.sub.1-C.sub.4) alkoxy, oxygen, sulfur or substituted congenersselected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes. 2. The compound according to claim 1, wherein: X is selected .[.form.]. .Iadd.from .Iaddend.amino, NR.sup.1 R.sup.2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; and when X=NR.sup.1 R.sup.2 andR.sup.1=methyl or ethyl, R.sup.2=methyl or ethyl R is selected from R.sup.4 (CH.sub.2).sub.nCO-- or R.sup.4' (CH.sub.2).sub.nSO.sub.2--; and when R=R.sup.4 (CH.sub.2).sub.nCO-- and n=0, R.sup.4 is selected from .[.substituted (C.sub.6-C.sub.10)arylgroup with substitution selected from halo, (C.sub.1-C.sub.4)alkoxy, nitro, amino, or (C.sub.1-C.sub.2)alkoxycarbonyl;.]. (C.sub.1-C.sub.4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxyl-carbonyl,straight or branched butoxycarbonyl or allyl-oxycarbonyl; a substituted (C.sub.6-C.sub.10)aryl group with substitution selected from halo, (C.sub.1-C.sub.4)alkoxy, .Iadd.nitro, amino, .Iaddend.(C.sub.1-C.sub.4) alkoxycarbonyl,.Iadd.tri.Iaddend.halo-(C.sub.1-C.sub.3)alkyl group; (C.sub.1-C.sub.4)alkoxy group; C.sub.6-aryloxy group selected from phenoxy or substituted phenoxy with substitution selected from halo, (C.sub.1-C.sub.4)alkyl; (C.sub.7-C.sub.10)aralkyloxy group; vinyloxy or substituted vinyloxy group with substitution selected from (C.sub.1-C.sub.2)-alkyl; R.sup.aR.sup.b amino(C.sub.1-C.sub.4)alkoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl,n-propyl, 1-methylethyl, n-butyl; or R.sup.aR.sup.b aminoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl; and whenR=R.sup.4 (CH.sub.2).sub.nCO-- and n=1-4, R.sup.4 is selected from amino; monosubstituted amino selected from straight or branched (C.sub.1-C.sub.6)alkyl-amino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino.Iadd., said(C.sub.1-C.sub.6)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl,2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl.Iaddend.; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, .[.monomethylbenzylamino, piperidinyl, morpholinyl.]. , 1-imidazolyl, .Iadd.or .Iaddend.1-pyrrolyl .[.or 1-(1,2,3-triazolyl).]. ; a substituted (C.sub.6-C.sub.10)aryl group with substitution selected from halo, (C.sub.1-C.sub.4)alkoxy, nitro, amino, (C.sub.1-C.sub.4)alkoxycarbonyl; acyloxy or haloacyloxygroup selected from acetyl, propionyl or chloroacetyl; (C.sub.1-C.sub.4)alkoxy group; R.sup.aR.sup.b amino(C.sub.1-C.sub.4)alkoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl,1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)alkyl, O, S, --NH, --NOB and B is selected from hydrogen or(C.sub.1-C.sub.3)alkyl; or R.sup.aR.sup.b aminoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is(CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W--(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)-alkyl, O, S, .[.--NY.]. .Iadd.--NH.Iaddend., --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)-alkyl; halo(C.sub.1-C.sub.3)-alkyl group; (C.sub.1.Iadd.-.Iaddend.C.sub.4)alkoxycarbonylamino selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; .[.and when R.dbd.R.sup.4'(CH.sub.2).sub.nSO.sub.2-- and n=0, R.sup.4' is selected from a substituted (C.sub.6-C.sub.10)aryl group with substitution selected from halo, (C.sub.1-C.sub.4)alkoxy, nitro, (C.sub.1-C.sub.4) alkoxycarbonyl;.]. R.sup.5 is selected from hydrogen; straight or branched (C.sub.1-C.sub.3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; R.sup.6 is selected from hydrogen; straight or branched (C.sub.1-C.sub.3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; with the provisothat R.sup.5 and R.sup.6 cannot both be hydrogen; or R.sup.5 or R.sup.6 taken together are --(CH.sub.2).sub.2W(CH.sub.2).sub.2--, wherein W is selected from (CH.sub.2).sub.q and q=0-1, --NH, --N(C.sub.1-C.sub.3)-alkyl, --N(C.sub.1-C.sub.4)alkoxy,oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes. 3. The compound according to claim 1 wherein said inorganic salts comprise hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate. 4. The compound according to claim 1 wherein said organic salts comprise acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate, alkylsulfonate or arylsulfonate. 5. The compound according to claim 1 wherein said metal complexes comprise aluminium, calcium, iron, magnesium, manganese and complex salts. 6. A compound according to claim 1 [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[(trifluoroacetyl)amino]-2-naphthacenecarboxamide sulfate. 7. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[(methoxyacetyl)amino]-1,11-dioxo-2-naphthacenec- arboxamide. 8. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-[(4-Bromo-1-oxobutyl)amino]-4,7-bis(dimethyl- amino)-1,4, 4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. 9. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[(1-oxo-2-propenyl)amino]-2-naphthacenecarboxamide. 10. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-[[(Acetyloxy)acetyl]amino]-4,7-bis (dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10, 12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfide. 11. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-(Benzoylamino)-4,7-bis(dimethylamino)- 1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide. 12. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(4-methyoxybenzoyl)amin- o]-1,11-dioxo-2-naphthacenecarboxamide. 13. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(2-methylbenzoyl)amino]- -1,11-dioxo-2-naphthacenecarboxamide. 14. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[(2-fluorobenzoyl)amino]-- 1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2-naphathacenecarboxamide. 15. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(pentafluorobenzoyl)a- mino]-1,11 -dioxo-2-naphthacenecarboxamide hydrochloride. 16. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5 , 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[3-(trifluoromethyl)benzoyl]amino]-2-naphthacenecarboxamide. 17. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[(2-furanylcarbonyl)amino- ]- 1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. 18. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-9-[(2-thienylcarbonyl)amino]-2-naphthacenecarboxamide. 19. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[ (4-nitrobenzonyl)amino]-1, 11-dioxo-2-naphthacenecarboxamide. 20. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-[(4-Aminobenzoyl)amino]-4,7-bis-dimethylamin- o)- 1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamidesulfate. 21. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-[[(4-dimethylamino)benzoyl]amino]-1,4,4a,5,5a,6,11- ,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. 22. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[2-[[(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a, 7,10,10a,12-octahydro-1,8,10a, 11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]- 2-oxoethyl]carbamic acid 1,1-dimethylethylester. 23. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-[(Aminoacetyl)amino]-4,7-bis(dimethylamino)- 1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono(trifluoroacetate). 24. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[(phenylsulfonyl)amino]-2-naphthacenecarboxamide. 25. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-[[(4-Chlorophenyl)sulfonyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide. 26. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4,7-Bis(dimethylamino)-1,4,4a,5, 5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[(3-nitrophenyl)sulfonyl]amino-1,11-dioxo-2-naph- thacenecarboxamide. 27. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,- 5a,6,11,12a-octahydro-3,10, 12,12a-tetrahydroxy-9-[ [(4-nitrophenyl)sulfonyl]amino]-1, 11-dioxo-2-naphthacenecarboxamide. 28. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5, 5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[(2-thienylsulfonyl)amino]-2-naphthacenecarboxamide. 29. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-[[(2-(Acetylamino)-4-methyl- 5-thiazolylsulfonyl]amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide. 30. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ (ethylsulfonyl)amino]-1, 4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide. 31. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-(formylamino)- 1,4,4a,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide. 32. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (methanesulfonyl)amino]-1,11-dioxo-2-naphthacenecarboxamide. 33. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(phenylmethoxy-)acetyl]amino]-2-naphthacenecarboxamide. 34. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphathacenyl]amino] oxoacetic acid ethyl ester. 35. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (hydroxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide. 36. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-[[(methylamino)acetyl] amino]-1, 4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-napthacenecarboxamide hydrochloride. 37. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid methyl ester. 38. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid ethenyl ester. 39. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[9-(Aminocarbonyl)-4,7-bis(dimethyl-amino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid ethenyl ester. 40. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[9-(Aminocarbonyl)-4,7-bis(dimethyl-amino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid 2-propenyl ester. 41. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate. 42. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (methoxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide hydrochloride. 43. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-[[(4-Bromo-1-oxobutyl)amino]-4,7bis(dimethyl- amino)-1,4,4a,5,5a,6,11,12a-octahydroxy- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate. 44. A compound according to claim 1 [4S-(4.alpha.,12a.alpha.)]-9-[[(Acetyloxy)acetyl]amino]-4,7-bis (dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10, 12,12a-tetrahydroxy-1,11-dioxo-2-napthacenecarboxamide. 45. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-(Benzolyamino)-4,7-bis(dimethylamino)- 1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetra-hydroxy- 1,11 -dioxo-2-naphthacenecarboxamide sulfate. 46. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11 -dioxo- 9-[[3-(trifluoromethyl)benzoyl]amino]-2-naphthacenecarboxamide hydrochloride. 47. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-[(4-Aminobenzoyl)amino]-4,7-bis(dimethylamin- o)- 1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-napthacenecarboxamide. 48. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-[[(4-dimethylamino)benzoyl]amino]-1,4,4a,5,5a,6,11- ,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride. 49. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a, 7,10,10a,12-octahydro-1,8,10a, 11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]- 2-oxoethyl]carbamic acid1,1-dimethylethyl ester hydrochloride. 50. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-9-[(Aminocarbonyl)-amino]-4,7-bis(dimethylamin- o)- 1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. 51. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ (ethylsulfonyl)amino]-1, 4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide hydrochloride. 52. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (methansulfonyl)amino]-1,11-dioxo-2-naphthacenecarboxamide sulfate. 53. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(phenylmethoxy-)acetyl]amino]-2-naphthacenecarboxamide hydrochloride. 54. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a, 6 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (hydroxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide sulfate. 55. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. 56. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid methyl ester sulfate. 57. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid (2-diethylamino)ethyl esterhydrochloride. 58. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid ethenyl ester sulfate. 59. A compound according to claim 1, [7S-(7.alpha.,10a.alpha.)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid 2-propenyl ester hydrochloride. 60. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-[[(diethylamino) acetyl]amino]-1, 4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide sulfate. 61. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-[[(diethylamino) acetyl]amino]-1, 4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide hydrochloride. 62. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-[[(diethylamino) acetyl]amino]-1, 11-dioxo-2-naphthacenecarboxamide. 63. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 64. A compound according to claim 1, [4S-(4.alpha.,12a.alpha.)]-4, 7-Bis(dimethylamino)-9-(chloroacetylamino)- 1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide. 65. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(Chloroacetyl)amino]-4,7-bis(dimethylamino)-1,4- ,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 66. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,- 4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 67. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,- 4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide (free base). 68. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,- 4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrobromide. 69. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrobromide. 70. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrobromide. 71. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 9-[[(methylamino)acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 72. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-4-morpholineacetamide dihydrochloride. 73. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ [(ethyamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a,-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 74. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[[(Cyclopropylamino)acetyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a,-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 75. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ [(butylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 76. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[[(Diethylamino)acetyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 77. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide dihydrochloride. 78. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahy- dro-3,10,12,12a-tetrahydroxy-9-[ [[(2-methylpropyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 79. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro-1,8,10a, 11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-1-piperidineacetamide dihydrochloride. 80. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 12-dioxo-2-naphthacenyl]-1H-imidazole- 1-acetamide dihydrochloride. 81. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(propylamino)acetyl]amino]-2-naphthacenecarboxamide dihydrochloride. 82. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]a- mino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. 83. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ [(hexylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 84. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[2-(dimethylamino)-1-oxo- propyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10, 12,12a-tetrahydroxy-1,11-dioxo-2-napthacenecarboxamide dihydrochloride. 85. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[2-(methylamino)- 1-oxo-propyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 86. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro-1,8,10a, 11-tetrahydroxy-10, 12-dioxo-2-naphthacencyl]-alphamethyl-1-pyrrolidineacetamide dihydrochloride. 87. A compound according to claim 1 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[4-(dimethylamino)-1-oxo- butyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10, 12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 88. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[[(Butylmethylamino)acetyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecenecarboxamide dihydrochloride. 89. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahy- dro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(pentylamino)acetyl]amino]-2-naphthacenecarboxamide dihydrochloride. 90. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahy- dro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(phenylmethyl)amino]acetyl]amino]-2-naphthacenecarboxamide dihydrochloride. 91. A compound according to claim 1, [7S-(7alpha,10aalpha) ]-N-[2-[ [9-(Aminocarbonyl) -4,7-bis(dimethylamino)-5,5a,6,6a,7,10a,12-octahydro-1,8, 10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]amino]- 2-oxoethyl]glycine. 92. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]a- mino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-pyrrolidinylmethyl)- 2-naphthacenecarboxamide. 93. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]a- mino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(4-morpholinylmethyl)- 2-naphthacenecarboxamide. 94. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]a- mino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-piperidinylmethyl)-2-naphthacene- cearboxamide. 95. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro-1,8, 10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-1-azetidineacetamide. 96. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[[(Cyclobutylamino)acetyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride. 97. A pharmaceutical composition of matter comprising a compound according to claim 1 in association with a pharmaceutically acceptable carrier. 98. A veterinary composition which comprises a pharmacologically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier. .Iadd.99. A compound of the formula ##STR00224## wherein: X is selected from amino, NR.sup.1 R.sup.2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R.sup.1 is selected from hydrogen, methyl, ethyl, n-propyl,1-methylethyl, n-butyl and 1-methylpropyl; R.sup.2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR.sup.1 R.sup.2 and R.sup.1=hydrogen, R.sup.2=methyl, ethyl,n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R.sup.1=methyl or ethyl, R.sup.2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R.sup.1=n-propyl,R.sup.2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R.sup.1=1-methylethyl, R.sup.2=n-butyl, 1-methylpropyl or 2-methylpropyl; and when R.sup.1=n-butyl, R.sup.2=n-butyl, 1-methylpropyl or 2-methypropyl; and whenR.sup.1=1-methylpropyl, R.sup.2=2-methylpropyl; R is selected from R.sup.4 (CH.sub.2).sub.nCO-- or R.sup.4' (CH.sub.2).sub.nSO.sub.2--; and n=0-4; and when R=R.sup.4 (CH.sub.2).sub.nCO-- and n=0, R.sup.4 is selected from amino; monosubstituted aminoselected from straight or branched (C.sub.1-C.sub.6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl,morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); a substituted (C.sub.3-C.sub.6)cycloalkyl group with substitution selected from cyano, amino or (C.sub.1-C.sub.3)acyl; a substituted (C.sub.6-C.sub.10)aryl group withsubstitution selected from halo, (C.sub.1-C.sub.4)alkoxy, trihalo (C.sub.1-C.sub.3)-alkyl, nitro, amino, cyano, (C.sub.1-C.sub.4)alkoxycarbonyl (C.sub.1-C.sub.3)alkylamino or carboxy; .alpha.-amino-(C.sub.1-C.sub.4)alkyl selected from aminomethyl,.alpha.-aminoethyl, .alpha.-aminopropyl or .alpha.-amino-butyl; carboxy (C.sub.2-C.sub.4)-alkylamino selected from aminoacetic acid, .alpha.-aminobutyric acid or .alpha.-aminopropionic acid and the optical isomers thereof; (C.sub.7-C.sub.9)aralkylamino; (C.sub.1-C.sub.4)alkoxycarbonylamino substituted (C.sub.1-C.sub.4) alkyl group; .alpha.-hydroxy(C.sub.1-C.sub.3)alkyl selected from hydroxymethyl, .alpha.-hydroxyethyl or .alpha.-hydroxy-1-methylethyl or.alpha.-hydroxypropyl; .alpha.-mercapto (C.sub.1-C.sub.3)alkyl selected from mercaptomethyl, .alpha.-mercaptoethyl, .alpha.-mercapto-1-methylethyl or .alpha.-mercaptopropyl; halo-(C.sub.1-C.sub.3)alkyl group; a heterocycle selected from the groupconsisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ringfused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl,propionyl, chloroacetyl, trifluoroacetyl; (C.sub.3-C.sub.6)cycloalcylcarbonyl, (C.sub.6-C.sub.10)aroyl selected from benzoyl or naphthoyl; halo substituted (C.sub.6-C.sub.10)aroyl; (C.sub.1-C.sub.4) alkylbenzoyl, or (heterocycle)-carbonyl, theheterocycle as defined hereinabove; (C.sub.1-C.sub.4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; a substituted vinyl group withsubstitution selected from halogen, halo(C.sub.1-C.sub.3)alkyl, or a substituted (C.sub.6-C.sub.10)aryl group with substitution selected from halo, (C.sub.1-C.sub.4)-alkoxy, trihalo(C.sub.1-C.sub.3)alkyl, nitro, amino, cyano,(C.sub.1-C.sub.4)alkoxycarbonyl, (C.sub.1-C.sub.3)alkylamino or carboxy; (C.sub.1-C.sub.4)alkoxy group; C.sub.6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C.sub.1-C.sub.4) alkyl, nitro, cyano, thiol,amino, carboxy, di(C.sub.1-C.sub.3)alkylamino; (C.sub.7-C.sub.10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C.sub.1-C.sub.4)alkyl, cyano, carboxy, or (C.sub.6-C.sub.10)aryl selected from phenyl,.alpha.-naphthyl or .beta.-naphthyl; R.sup.aR.sup.b amino(C.sub.1-C.sub.4)alkoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or (CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)alkyl, O, S, --NH, --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl; or R.sup.aR.sup.baminoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or--(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)alkyl, O, S, --NH, --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl; and when R=R.sup.4 (CH.sub.2).sub.nCO-- and n=1-4, R.sup.4 is selected from amino; a substituted (C.sub.3-C.sub.6)cycloalkyl group with substitution selected from cyano, amino or (C.sub.1-C.sub.3)acyl; a substituted(C.sub.6-C.sub.10)-aryl group with substitution selected from halo, (C.sub.1-C.sub.4)-alkoxy,trihalo(C.sub.1-C.sub.3)alkyl, nitro, amino, cyano, (C.sub.1-C.sub.4)alkoxycarbonyl, (C.sub.1-C.sub.3)alkylamino or carboxy; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichlorocetyl, (C.sub.3-C.sub.6)cycloalkylcarbonyl,(C.sub.6-C.sub.10)aroyl selected from benzoyl or naphthoyl, halo substituted (C.sub.6-C.sub.10)aroyl, (C.sub.1-C.sub.4)alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C.sub.1-C.sub.4)alkoxy; C.sub.6-aryloxy selectedfrom phenoxy or substituted phenoxy with substitution selected from halo, (C.sub.1-C.sub.4)-alkyl, nitro, cyano, thiol, amino, carboxy, di(C.sub.1-C.sub.3)-alkylamino; (C.sub.7-C.sub.10)aralkyloxy; (C.sub.1-C.sub.3)alkylthio group selected frommethylthio, ethylthio, propylthio or allythio; C.sub.6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C.sub.1-C.sub.4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C.sub.1-C.sub.3)alkylamino; C.sub.6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C.sub.1-C.sub.4)alkoxy, trihalo(C.sub.1-C.sub.3)alkyl, nitro, amino, cyano, (C.sub.1-C.sub.4)alkoxycarbonyl,(C.sub.1-C.sub.3)alkylamino or carboxy; (C.sub.7-C.sub.8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C.sub.1-C.sub.6)-alkylamino with the alkyl selected from methyl, ethyl,n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl,1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C.sub.2-C.sub.5)azacycloalkyl group; a carboxy(C.sub.2-C.sub.4) alkylamino group with the carboxy alkyl selected from aminoacetic acid, .alpha.-aminopropionic acid, .alpha.-aminobutyric acid and the opticalisomers thereof; .alpha.-hydroxy(C.sub.1-C.sub.3)alkyl selected from hydroxymethyl, .alpha.-hydroxyethyl or .alpha.-hydroxy-1-methylethyl or .alpha.-hydroxypropyl; halo(C.sub.1-C.sub.3)alkyl group; acyl or haloacyl selected from acetyl, propionyl,chloroacetyl, trifluoroacetyl; (C.sub.3-C.sub.6)cycloalkylcarbonyl; (C.sub.6-C.sub.10)aroyl selected from benzoyl or naphthoyl; halo substituted (C.sub.6-C.sub.10)aroyl; (C.sub.1-C.sub.4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle asdefined hereinabove; (C.sub.1-C.sub.4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C.sub.1-C.sub.4)alkoxycarbonyl group selected frommethoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R.sup.aR.sup.b-amino(C.sub.1-C.sub.4)alkoxy group wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)alkylselected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m m=2-6 or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)-alkyl, O, S, --NH,--NOB, and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl; or R.sup.aR.sup.b aminoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl,2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)-alkyl, O, S, --NH, --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl, and when R=R.sup.4,(CH.sub.2)SO.sub.2-- and n=0 R.sup.4' is selected from amino; monosubstituted amino selected from straight or branched (C.sub.1-C.sub.6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected fromdimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazoyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); a substituted (C.sub.3-C.sub.6)cycloalkyl group with substitution selected fromcyano, amino or (C.sub.1-C.sub.3)acyl; halo(C.sub.1-C.sub.3)alkyl group; a heterocycle as defined hereinabove; R.sup.aR.sup.b amino (C.sub.1-C.sub.4) alkoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)-alkyl selected frommethyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W--(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3) alkyl, O, S, --NH, --NOB and B isselected from hydrogen or (C.sub.1-C.sub.3)-alkyl; or R.sup.aR.sup.b aminoxy group, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, or2-methyl-propyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3) alkyl, O, S, --NH, --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3) alkyl; and whenR=R.sup.4' (CH.sub.2).sub.nSO.sub.2-- and n=1-4, R.sup.4' is selected from (C.sub.1-C.sub.4)carboxyalkyl; a substituted (C.sub.3-C.sub.6)cyclalkyl group with substitution selected from cyano, amino or (C.sub.1-C.sub.3)-acyl; (C.sub.1-C.sub.4)alkoxy; C.sub.6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C.sub.1-C.sub.3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C.sub.1-C.sub.3) alkylamino; (C.sub.7-C.sub.10)aralkyloxy; R.sup.aR.sup.b amino(C.sub.1-C.sub.4) alkoxy, wherein R.sup.aR.sup.b is a straight or branched (C.sub.1-C.sub.4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or--(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from --N(C.sub.1-C.sub.3)alkyl, O, S, --NH or --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl; or R.sup.aR.sup.b aminoxy group, wherein R.sup.aR.sup.b is a straight or branched(C.sub.1-C.sub.4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R.sup.aR.sup.b is (CH.sub.2).sub.m, m=2-6, or --(CH.sub.2).sub.2W(CH.sub.2).sub.2-- wherein W is selected from--N(C.sub.1-C.sub.3)alkyl, O, S, --NH, --NOB and B is selected from hydrogen or (C.sub.1-C.sub.3)alkyl; (C.sub.1-C.sub.3) alkylthio selected from methylthio, ethylthio or n-propylthio; C.sub.6-arylthio selected from phenylthio or substituted phenylthiowith substitution selected from halo, (C.sub.1-C.sub.3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C.sub.1-C.sub.3)alkylamino; (C.sub.7-C.sub.8) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight orbranched (C.sub.1-C.sub.6)alkyl- amino group the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl,1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C.sub.1-C.sub.3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C.sub.3-C.sub.6) cycloalkylcarbonyl; (C.sub.6-C.sub.10) aroyl selected from benzoyl or naphthoyl; halo substituted (C.sub.6-C.sub.10)aroyl, (C.sub.1-C.sub.4) alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C.sub.1-C.sub.4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; and the pharmacologically acceptable organic and inorganic salts or metalcomplexes..Iaddend. .Iadd.100. A compound of formula I ##STR00225## wherein X is selected from amino, NR.sup.1R.sup.2, or halogen, the halogen is selected from bromine, chlorine, fluorine or iodine, and when X is NR.sup.1R.sup.2, R.sup.1 is methyl or ethyl andR.sup.2 is methyl or ethyl; R is R.sup.4(CH.sub.2).sub.nCO--; n=1-4; and R.sup.4 is monosubstituted or disubstituted amino selected from straight or branched (C.sub.1-C.sub.6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl,1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl,1,3-dimethybutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes..Iaddend. .Iadd.101. A compound of formula I ##STR00226## wherein X is N(CH.sub.3).sub.2 and R is R.sup.4(CH.sub.2).sub.nCO-- where n=1-4 and R.sup.4 is monosubstituted or disubstituted amino selected from straight or branched(C.sub.1-C.sub.6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl,1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes..Iaddend. .Iadd.102. A compound of formula I ##STR00227## wherein X is N(CH.sub.3).sub.2 and R is R.sup.4(CH.sub.2).sub.nCO-- where n=1 and R.sup.4 is monosubstituted or disubstituted amino selected from straight or branched (C.sub.1-C.sub.6)alkylamino,with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl,2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes..Iaddend. .Iadd.103. A compound of the following structure: ##STR00228## wherein R.sup.4 is a monsubstituted straight or branched C.sub.4-alkylamino, and pharmacologically acceptable organic and inorganic salts or metal complexes..Iaddend.
Description: